Top Markets
Coin of the day
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Rank in Stocks #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Share Price
$2.72
Last synced: 2023-10-19
Market Cap
$111.47M
Change (1 day)
-0.73%
Change (1 year)
0.00%
Country
US
Trade Talaris Therapeutics, Inc. (TALS)

Category

Dividend history for Talaris Therapeutics, Inc. (TALS)
Talaris Therapeutics, Inc. (stock symbol: TALS) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Talaris Therapeutics, Inc. (TALS) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH